Literature DB >> 9291333

Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma.

J A Zaia1, G M Gallez-Hawkins, B R Tegtmeier, A ter Veer, X Li, J C Niland, S J Forman.   

Abstract

Late occurrence of cytomegalovirus (CMV) disease after day 100 after bone marrow transplantation has become an increasing problem; whether a quantitative measurement of CMV DNA in plasma by polymerase chain reaction (P-PCR) could be predictive of such disease was investigated. In a prospective study, 117 subjects undergoing allogeneic marrow transplantation were followed for 120 days with weekly CMV blood cultures, with day 35 bronchoalveolar lavage CMV cultures, with weekly CMV P-PCR, and with clinical follow-up for an additional 1-2 years. Despite preemptive ganciclovir, CMV disease occurred in 9% of subjects, with a median time of onset of 176 days. Quantitative CMV P-PCR was associated with the late development of CMV disease (P = .01). Of 43 subjects with positive P-PCR results, 23% developed CMV disease, but no disease occurred in the 74 subjects with negative P-PCR (P < .001), despite the fact that 22% had CMV isolated from lung lavage fluid and 32% had CMV isolated from blood.

Entities:  

Mesh:

Year:  1997        PMID: 9291333     DOI: 10.1086/517301

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  A highly sensitive assay for detection and quantitation of human cytomegalovirus DNA in serum and plasma by PCR and electrochemiluminescence.

Authors:  R Boom; C Sol; J Weel; Y Gerrits; M de Boer; P Wertheim-van Dillen
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

Review 2.  Human cytomegalovirus resistance to antiviral drugs.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 3.  How we treat cytomegalovirus in hematopoietic cell transplant recipients.

Authors:  Michael Boeckh; Per Ljungman
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

4.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

5.  Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.

Authors:  Michael Boeckh; W Garrett Nichols; Roy F Chemaly; Genovefa A Papanicolaou; John R Wingard; Hu Xie; Karen L Syrjala; Mary E D Flowers; Terry Stevens-Ayers; Keith R Jerome; Wendy Leisenring
Journal:  Ann Intern Med       Date:  2015-01-06       Impact factor: 25.391

6.  Molecular methods for cytomegalovirus surveillance in bone marrow transplant recipients.

Authors:  Adriana Weinberg; Debra Schissel; Roger Giller
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

7.  How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation.

Authors:  Hermann Einsele; Per Ljungman; Michael Boeckh
Journal:  Blood       Date:  2020-05-07       Impact factor: 22.113

8.  Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.

Authors:  So-Youn Park; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo; Heungsup Sung; Mi-Na Kim; Dae-Young Kim; Jung-Hee Lee; Je-Hwan Lee; Kyoo-Hyung Lee; Sung-Han Kim
Journal:  J Clin Microbiol       Date:  2011-10-26       Impact factor: 5.948

9.  Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia.

Authors:  Guenther Koehne; Aisha Hasan; Ekaterina Doubrovina; Susan Prockop; Eleanor Tyler; Gloria Wasilewski; Richard J O'Reilly
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-29       Impact factor: 5.742

10.  An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients.

Authors:  Margaret Pollack; Judson Heugel; Hu Xie; Wendy Leisenring; Jan Storek; Jo-Anne Young; Manisha Kukreja; Ronald Gress; Marcie Tomblyn; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-10       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.